LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.25 -1.57

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.25

Максимум

1.33

Ключови измерители
By Trading Economics
Приходи	17M -26M
EPS	-0.43
Марж на печалбата	-2,190.837
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+134.38% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-24M 79M
Предишно отваряне	2.82
Предишно затваряне	1.25

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.12.2025 г., 22:13 ч. UTC

Печалби

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9.12.2025 г., 21:40 ч. UTC

Печалби

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9.12.2025 г., 18:51 ч. UTC

Придобивния, сливания и поглъщания

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9.12.2025 г., 16:57 ч. UTC

Значими двигатели на пазара

Clear Secure Rises on Medicare Identity Verification Contract

9.12.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9.12.2025 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings Stake in Lenovo Now at 32.34%

9.12.2025 г., 23:45 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9.12.2025 г., 23:44 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9.12.2025 г., 23:43 ч. UTC

Придобивния, сливания и поглъщания

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9.12.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9.12.2025 г., 22:42 ч. UTC

Печалби

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9.12.2025 г., 21:36 ч. UTC

Печалби

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9.12.2025 г., 20:28 ч. UTC

Пазарно говорене

Oil Futures Decline for Second Straight Session -- Market Talk

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9.12.2025 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Teck Reports Voting Results From Special Meeting of Hldrs

9.12.2025 г., 20:26 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9.12.2025 г., 20:21 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9.12.2025 г., 19:52 ч. UTC

Печалби

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9.12.2025 г., 19:17 ч. UTC

Печалби

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.12.2025 г., 17:11 ч. UTC

Печалби

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

134.38% нагоре

12-месечна прогноза

Среден 3 USD 134.38%

Висок 4 USD

Нисък 2 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.